Bluejay acknowledges NorthStrive's acquisition suggestion, reiterates focus on Symphony platform

Bluejay Diagnostics, Inc.

Responds to NorthStrive Fund II LP letter proposing acquisition of Phase-1-ready chronic cough therapeutic program.
Board and management will evaluate the opportunity but emphasize current priorities: Symphony platform, SYMON II study, FDA submission.
Notes NorthStrive did not identify the potential counterparty; requests additional diligence information if available.
Reaffirms commitment to fiduciary duties under Delaware law and preserving cash resources.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.